scispace - formally typeset
J

Joachim Yahalom

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  416
Citations -  25023

Joachim Yahalom is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Radiation therapy & Lymphoma. The author has an hindex of 76, co-authored 369 publications receiving 22631 citations. Previous affiliations of Joachim Yahalom include University of California, Davis & Northwestern University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Daniel J. Klionsky, +235 more
- 16 Feb 2008 - 
TL;DR: A set of guidelines for the selection and interpretation of the methods that can be used by investigators who are attempting to examine macroautophagy and related processes, as well as by reviewers who need to provide realistic and reasonable critiques of papers that investigate these processes are presented.
Journal Article

A Novel Response of Cancer Cells to Radiation Involves Autophagy and Formation of Acidic Vesicles

TL;DR: The accretion of AVO in surviving progenies of irradiated cells, and the increased incidence of clonogenic death after inhibition of vacuolar H+-ATPase suggest that formation of acidic organelles represents a novel defense mechanism against radiation damage.
Journal ArticleDOI

Treatment for Primary CNS Lymphoma: The Next Step

TL;DR: Increasing the dose of MTX and adding procarbazine and vincristine improved disease control and overall survival in patients with newly diagnosed PCNSL and younger patients in particular fared extremely well with this treatment regimen.
Journal ArticleDOI

Long-term survival in primary CNS lymphoma.

TL;DR: Combined modality therapy for PCNSL has improved survival, but relapse is common and late neurologic toxicity is a significant complication, and efficacious but less neurotoxic regimens need to be developed for older patients.
Journal ArticleDOI

Combined modality therapy for primary CNS lymphoma.

TL;DR: The addition of chemotherapy to cranial RT for initial treatment ofPCNSL significantly improved disease-free survival and contributed to overall survival; all non-AIDS patients with newly diagnosed PCNSL should be considered for combined modality therapy.